食品与发酵工业 >

2025 , Vol. 51 >Issue 21: 85 - 94

DOI: https://doi.org/10.13995/j.cnki.11-1802/ts.042007

研究报告

基于超高效液相色谱-四极杆轨道阱高分辨-质谱技术结合网络药理学研究卡森露剂干预非酒精性脂肪性肝炎的作用机制

  • 依明·尕哈甫 ,
  • 买买提江·阿布都瓦克 ,
  • 阿迪莱·艾合麦提托合提 ,
  • 马强强 ,
  • 艾尼娃尔·艾克木
展开
  • 1(新疆医科大学 药学院,新疆 乌鲁木齐,830017)
    2(新疆和田学院 药学院,新疆 和田,848000)
    3(新疆和田中药民族医药工程技术研究中心,新疆 和田,848000)
    4(新疆维吾尔自治区维吾尔药材及制剂质量控制工程研究中心,新疆 和田,848000)
    5(新疆和田特色中医药研究重点实验室,新疆 和田,848000)
第一作者：博士,副教授(艾尼娃尔·艾克木教授为通信作者,E-mail:115149469@qq.com)

收稿日期: 2024-12-31

  修回日期: 2025-03-26

  网络出版日期: 2025-11-21

基金资助

新疆维吾尔自治区重大科技专项(2022A03019-3);和田地区本级科技计划项目(202312)

收起

Mechanism of Kasen distillate to intervence in non-alcoholic steatohepatitis based on UPLC-QE-MS combined with network pharmacology

  • YIMING·Gahafu ,
  • MAIMAITIJIANG·Abuduwake ,
  • ADILAI·Aihemaitituoheti ,
  • MA Qiangqiang ,
  • AINIWAER·Aikemu
Expand
  • 1(School of Pharmacy, Xinjiang Medical University, Urumqi 830017, China)
    2(School of Pharmacy, Xinjiang Hetian College, Hetian 848000, China)
    3(Xinjiang Hetian Traditional Chinese Medicine and Ethnic Medicine Engineering Technology Research Center, Hetian 848000, China)
    4(Engineering Research Center of Quality Control of Uyghur Medicinal Materials and Preparation, Hetian 848000, China)
    5(Xinjiang Key Laboratory of Hetian Characteristic Chinese Traditional Medicine Research, Hetian 848000, China)

Received date: 2024-12-31

  Revised date: 2025-03-26

  Online published: 2025-11-21

Fold

摘要

该研究旨在基于超高效液相色谱串联质谱(ultra-high performance liquid chromatography-mass spectrometry,UPLC-MS)技术鉴定卡森露剂活性成分,通过网络药理学结合细胞实验,预测卡森露剂干预非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)的可能机制。利用SwissADME、SwissTargetPrediction、GeneCards、DrugBank等数据库筛选卡森露剂活性成分与NASH的交集靶点,运用David数据库对核心靶点进行富集分析,使用AutoDockTools软件进行分子对接并开展细胞验证实验。结果表明,卡森露剂共有32种活性成分并对应181个共有靶点;GO功能富集2 764个条目,KEGG通路主要涉及脂质与动脉粥样硬化、糖尿病并发症AGE-RAGE信号通路及TNF信号通路等;分子对接表明关键成分和核心靶点存在良好的结合力;细胞实验验证了卡森露剂可以降低HepG2细胞内甘油三酯、总胆固醇、低密度脂蛋白胆固醇水平及丙氨酸转氨酶、天冬氨酸转氨酶活性并升高高密度脂蛋白胆固醇水平,升高p-Akt1/Akt1(磷酸化水平)及Bcl-2蛋白表达,降低p-STAT3/STAT3(磷酸化水平)及IL-1β蛋白表达水平。卡森露剂可能通过调控炎症通路改善NASH。

关键词： 卡森露剂; UPLC-MS; 网络药理学; 细胞实验; 非酒精性脂肪性肝炎

本文引用格式

依明·尕哈甫 , 买买提江·阿布都瓦克 , 阿迪莱·艾合麦提托合提 , 马强强 , 艾尼娃尔·艾克木 . 基于超高效液相色谱-四极杆轨道阱高分辨-质谱技术结合网络药理学研究卡森露剂干预非酒精性脂肪性肝炎的作用机制[J]. 食品与发酵工业, 2025 , 51(21) : 85 -94 . DOI: 10.13995/j.cnki.11-1802/ts.042007

Abstract

This study aimed to identify the active ingredients of Kasen distillate based on ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) technology and to predict the possible mechanism of Kasen distillate intervention in non-alcoholic steatohepatitis (NASH) through network pharmacology combined with cell experiment.Databases such as SwissADME, SwissTarget Prediction, GeneCards, and DrugBank were used to screen the intersection targets between the active ingredients of Kasen distillate and NASH, the David database was used to enrich and analyze the core targets, and molecular docking was conducted and cell validation experiments were carried out.The results showed that there were a total of 32 active ingredients in Kasen distillate, corresponding to 181 common targets;2 764 entries were enriched for GO function, KEGG pathways were mainly involved in lipid and atherosclerosis, AGE-RAGE signaling pathway and TNF signaling pathway, et al;Molecular docking had verified the good binding affinity between the key components and the core targets;Cell experiments had confirmed that Kasen distillate could reduce the levels of TG, TC, LDL-C and the activities of ALT, AST, increase the level of HDL-C, elevate the protein expressions of p-Akt1/Akt1 (phosphorylation level) and Bcl-2, reduce the protein expressions of p-STAT3/STAT3 (phosphorylation level) and IL-1β in HepG2 cells.Kasen distillate may improve non-alcoholic steatohepatitis by regulating inflammatory pathways.

Key words： Kasen distillate; UPLC-MS; network pharmacology; cell experiments; non-alcoholic steatohepatitis

参考文献

[1] 李凤, 李茂微, 王雨杉.非酒精性脂肪肝病的治疗模式和潜在疗法[J].临床肝胆病杂志, 2024, 40(10):2082-2086.
LI F, LI M W, WANG Y S.Therapeutic paradigms and potential therapies for nonalcoholic steatohepatitis[J].Journal of Clinical Hepatology, 2024, 40(10):2082-2086.
[2] QU H D, ZHANG D, LIU J L, et al.Therapeutic targeting of PKM2 ameliorates NASH fibrosis progression in a macrophage-specific and liver-specific manner[J].Engineering, 2024, 41:189-203.
[3] 孙召珲, 杨臻峥, 郑晓南.非酒精性脂肪性肝病的靶点发现与药物研发进展[J].中国新药杂志, 2023, 32(23):2394-2402.
SUN Z H, YANG Z Z, ZHENG X N.Progress in target discovery and drug development for non-alcohol fatty liver disease[J].Chinese Journal of New Drugs, 2023, 32(23):2394-2402.
[4] 凡杭, 陈剑, 梁呈元, 等.菊苣化学成分及其药理作用研究进展[J].中草药, 2016, 47(4):680-688.
FAN H, CHEN J, LIANG C Y, et al.Advance in studies on chemical constituents of Cichorii Herba and their pharmacological effects[J].Chinese Traditional and Herbal Drugs, 2016, 47(4):680-688.
[5] 祁淑雯, 仲烨伟, 阿达来提·阿布都热西提, 等.基于靶向代谢组学技术研究毛菊苣对肥胖小鼠粪便胆汁酸谱的影响[J].中国实验动物学报, 2024, 32(9):1122-1138.
QI S W, ZHONG Y W, ADALAITI A, et al.Effect of Cichorium glandulosum Boiss.et Huet.on fecal bile acid profile in obese mice based on targeted metabolomics technique[J].Acta Laboratorium Animalis Scientia Sinica, 2024, 32(9):1122-1138.
[6] 苏林洁, 吕博, 马斌, 等.毛菊苣正丁醇萃取物中母菊素含量测定及其对大鼠肝纤维化保护作用[J].中国药理学通报, 2023, 39(9):1731-1739.
SU L J, LYU B, MA B, et al.Determination of content of matricin extracted from Cichorium glandulosum Boiss et Huet with n-butanol and its protective effect on hepatic fibrosis in rats[J].Chinese Pharmacological Bulletin, 2023, 39(9):1731-1739.
[7] 段贤春, 黄石, 彭代银, 等.网络药理学在中药复方研究中的应用[J].中国药理学通报, 2020, 36(3):303-308.
DUAN X C, HUANG S, PENG D Y, et al.Application of network pharmacology in the study of traditional Chinese medicine formula[J].Chinese Pharmacological Bulletin, 2020, 36(3):303-308.
[8] 马嘉慕, 董英, 魏静, 等.基于网络药理学与分子对接技术的保健食品白及五味子颗粒保胃护肝作用机制和功效成分含量测定研究[J].食品与发酵工业, 2023, 49(11):131-139.
MA J M, DONG Y, WEI J, et al.Study on gastric mucosa protection mechanism and content of functional component in Baji Wuweizi Granule based on network pharmacology and molecular docking[J].Food and Fermentation Industries, 2023, 49(11):131-139.
[9] 孙智珺, 叶阳梅, 王光新.白芍总苷体外抗非酒精性脂肪肝的作用机制研究[J].世界科学技术-中医药现代化, 2022, 24(7):2748-2754.
SUN Z J, YE Y M, WANG G X.Study on the action mechanism of total glycosides of peony against non-alcoholic fatty liver in vitro[J].Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology, 2022, 24(7):2748-2754.
[10] 李开楊, 郭震凡, 田新材, 等.祛脂愈肝汤对非酒精性脂肪性肝炎细胞脂质代谢及IL-17表达的影响[J].时珍国医国药, 2025, 36(10):1801-1806.
LI K Y, GUO Z F, TIAN X C, et al.Effect of Quzhi Yugan Decoction on lipid metabolism and IL-17 expression in non-alcoholic steatohepatitis cells[J].Journal of Li-Shizhen Traditional Chinese Medicine, 2025, 36(10):1801-1806.
[11] 颜伟泓, 张鸿燕, 李玲燕, 等.泽泻醇A对HepG2细胞脂质沉积的影响及其降脂活性研究[J].上海中医药杂志, 2024, 58(10):63-70.
YAN W H, ZHANG H Y, LI L Y, et al.Effect of alisol A on lipid deposition in HepG2 cells and its hypolipidemic activity research[J].Shanghai Journal of Traditional Chinese Medicine, 2024, 58(10):63-70.
[12] 张丽慧, 刘素彤, 张文娟, 等.基于ADPN/PI3K/AKT信号通路探讨化痰祛湿活血方改善非酒精性脂肪性肝炎大鼠炎症损伤的机制[J].中华中医药杂志, 2021, 36(10):5832-5837.
ZHANG L H, LIU S T, ZHANG W J, et al.Mechanism of Huatan Qushi Huoxue Formula in improving the inflammatory injury of rats with nonalcoholic steatohepatitis based on ADPN/PI3K/AKT signal pathway[J].China Journal of Traditional Chinese Medicine and Pharmacy, 2021, 36(10):5832-5837.
[13] 尚东方, 赵文霞, 赵晨露, 等.基于NLRP3/Caspase-1/GSDMD焦亡通路探讨涤浊化瘀方对非酒精性脂肪性肝炎小鼠的影响[J].中华中医药杂志, 2024, 39(11):6061-6065.
SHANG D F, ZHAO W X, ZHAO C L, et al.Mechanism of Dizhuo Huayu Decoction on nonalcoholic steatohepatitis mouse based on NLRP3/Caspase-1/GSDMD pyroptosis pathway[J].China Journal of Traditional Chinese Medicine and Pharmacy, 2024, 39(11):6061-6065.
[14] 祝娟娟, 程明亮, 赵雪珂, 等.蓝莓联合益生菌通过IL-22调控的JAK1/STAT3/BAX通路改善非酒精性脂肪性肝病的作用机制[J].临床肝胆病杂志, 2018, 34(9):1936-1944.
ZHU J J, CHENG M L, ZHAO X K, et al.Mechanism of action of blueberry combined with probiotics in improving nonalcoholic fatty liver disease by affecting the JAK1/STAT3/BAX signaling pathway regulated by interleukin-22[J].Journal of Clinical Hepatology, 2018, 34(9):1936-1944.
[15] 徐文轩, 宋汶轩, 喇孝瑾, 等.脂肝清方对NAFLD小鼠肝损伤及肝细胞凋亡的影响[J].中成药, 2023, 45(11):3583-3591.
XU W X, SONG W X, LA X J, et al.Effects of Zhiganqing Formula on liver injury and hepatocyte apoptosis in NAFLD mice[J].Chinese Traditional Patent Medicine, 2023, 45(11):3583-3591.
[16] 李越, 吴希泽, 潘嘉祥, 等.肝细胞脂肪变性影响巨噬细胞炎症反应加速动脉粥样硬化形成[J].浙江大学学报(医学版), 2023, 52(6):751-765.
LI Y, WU X Z, PAN J X, et al.Hepatocyte steatosis activates macrophage inflammatory response accelerating atherosclerosis development[J].Journal of Zhejiang University (Medical Sciences), 2023, 52(6):751-765.
[17] 杨君茹, 何玲玲, 高美欣, 等.糖基化修饰在代谢相关脂肪性肝病中作用研究进展[J].中国肝脏病杂志(电子版), 2022, 14(4):20-27.
YANG J R, HE L L, GAO M X, et al.Progress on glycosylation in metabolic dysfunction-associated fatty liver disease[J].Chinese Journal of Liver Diseases (Electronic Version), 2022, 14(4):20-27.
[18] 田晓玲, 蒋佳佳, 张彧, 等.中药多糖防治非酒精性脂肪性肝病作用机制研究进展[J].中草药, 2024, 55(17):6016-6025.
TIAN X L, JIANG J J, ZHANG Y, et al.Research progress on mechanism of traditional Chinese medicine polysaccharide in prevention and treatment of non-alcoholic fatty liver disease[J].Chinese Traditional and Herbal Drugs, 2024, 55(17):6016-6025.
[19] 单杉, 陈婷婷, 李南, 等.两种非酒精性脂肪性肝病小鼠模型的比较[J].中国药理学通报, 2022, 38(3):470-476.
SHAN S, CHEN T T, LI N, et al.Comparison of two methods for establishing non-alcoholic fatty liver disease model in mice[J].Chinese Pharmacological Bulletin, 2022, 38(3):470-476.
Options
文章导航

/

〈 〉

技术支持：北京玛格泰克科技发展有限公司